Astellas, Chromocell In Pain Pact Worth $515m-plus
This article was originally published in PharmAsia News
Executive Summary
Astellas will pay Chromocell $15m up front and could spend more than $500m on milestone fees under a license and collaboration agreement for Nav1.7 antagonists, including lead drug candidate CC8464 and backup compounds, for the treatment of neuropathic pain and other conditions.
You may also be interested in...
J.P. Morgan Executive Roundtable, Part 4: How Do You Determine A Drug’s Value To Patients, Payers, Partners?
Biopharma executives discuss the value of innovative medicines in the eyes of patients and payers, but before that companies must determine how partners or acquirers would value their drug candidates.
J.P. Morgan Executive Roundtable, Part 3: Financing Is Difficult, But Available For Drugs That Provide Value
Plunging biopharma company stock values and declining IPO activity have contributed to a more difficult financing environment, but money is still available for public and private drug developers whose products provide value in the eyes of patients and payers.
J.P. Morgan Executive Roundtable, Part 2: Women In Biopharma And The Path Forward
Women fill many roles in biopharma companies, but relatively few are in leadership positions. Executives who spoke with Scrip in a roundtable discussion during the J.P. Morgan Healthcare Conference earlier this month noted the disconnect, but saw some hope for improved gender diversity in the future.